Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
genevac-b
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
GeneVac-B is a recombinant DNA hepatitis B vaccine indicated for active immunization against hepatitis B virus (HBV) infection in individuals at risk of exposure to HBV-positive material. The vaccine contains purified hepatitis B surface antigen (HBsAg) produced in Hansenula polymorpha yeast and adsorbed on aluminum hydroxide as an adjuvant. It does not contain any material of human or animal origin. Upon administration, the HBsAg stimulates the immune system to produce antibodies (anti-HBs), providing protection against future HBV infection. Immunization with GeneVac-B reduces the incidence of acute and chronic hepatitis B, as well as complications such as cirrhosis and hepatocellular carcinoma[1][7][5]. The vaccine is available in pediatric (10 mcg/0.5 ml) and adult (20 mcg/1 ml) formulations for intramuscular injection.
- Brand names
- GeneVac-B
- Other names
- Gene Vac-BGenvac-B
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on genevac-b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on genevac-b.